Cytomegalovirus: neglected problem endangers pregnant women, children

Medscape Cytomegalovirus

Cytomegalovirus (CMV) hasn’t gotten the press accorded to Zika, yet it infects 2%-4% of pregnant women and is transmitted to the fetus. The resulting congenital infection in 40% of these cases can result in a host of serious problems that include brain maldevelopment and microcephaly. An article recently published in Medscape Family Medicine draws needed attention to his common but poorly recognized hazard.

“Congenital CMV is well recognized as a common, endemic congenital infection, infecting over 30,000 newborns each year in the United States. Although many newborns congenitally infected with CMV may have no symptoms or sequelae, up to 8000 each year will have in utero growth restriction; petechiae; liver and spleen disease; thrombocytopenia; congenital and progressive hearing loss; vision loss; brain maldevelopment syndromes; microcephaly; and permanent neurodevelopmental and motor disabilities such as cerebral palsy. In addition, fetal and neonatal death from in utero CMV occurs in approximately 400 babies each year.”

Cytomegalovirus awareness is low

Most people have heard of Zika but very few are aware of cytomegalovirus though it is a far more widespread problem.

“…despite this well-recognized and well-accepted public health impact, only 9%-15% of women of childbearing age, including those with graduate degrees and those entering medical school, have even heard of CMV.”

“CMV Knowledge Vaccine”

Just knowing that cytomegalovirus is a common infection and serious hazard in pregnancy is the start. Then there are three simple precautions based on the fact that young children commonly excrete CMV in their saliva and/or urine for a year and transmit it to their parents 45-53% of the time, often without either manifesting any symptoms. The paper cites three recommendations to reduce exposure:

  1. Not sharing food, drink, straws or eating utensils with young children;

  2. Not kissing young children on or around the mouth or lips; and

  3. Washing hands well after changing all diapers (wet with urine or dirty with stool) and wiping runny noses or mouth drool.

Unfortunately, the American College of Obstetrics and Gynecology (ACOG) has not supported active education of women about CMV risk. The author concludes:

The greatest risk reduction strategy available now to prevent CMV transmission to pregnant women is education about CMV. Patients; healthcare professionals, especially obstetricians and midwives; and public health agencies should be partners in providing women with factual information and allowing them to make informed choices regarding their pregnancy health and prevention of CMV. In other words, spread the word, not the virus.”

Thyroid autoimmunity and iron deficiency in pregnancy

European Journal of Endocrinology on thyroid autoimmunity in pregnancyThyroid autoimmunity and iron deficiency are both common in pregnancy, posing a risk for numerous adverse fetal and maternal outcomes, including miscarriage. A clinical study just published in the European Journal of Endocrinology the important connection between thyroid autoimmunity and low iron, both of which can be recognized at an early stage. The authors state:

“Thyroid disorders and iron deficiency (ID) are associated with obstetrical and fetal complications. Iron is essential for the normal functioning of thyroid peroxidase (TPO-abs) and ID is frequent during pregnancy. The aim of this study was to compare the prevalence of thyroid autoimmunity (TAI) and dysfunction during the first trimester of pregnancy in women with and without ID.”

They measured ferritin to determine iron status, TPO-abs (thyroid peroxidase antibodies) for thyroid autoimmunity, and thyroid-stimulating hormone (TSH) and free T4 (FT4) thyroid function. Note that their definitions for iron deficiency (ID) and thyroid autoimmunity (TAI) were extremely ‘generous’ with ID defined as ferritin <15µg/L and TAI as TPO-abs >60kIU/L. Practitioners in this country should also note their definition of subclinical hypothyroidism (SCH) as TSH was >2.5mIU/L.

Thyroid autoimmunity and iron deficiency are common

Their data also demonstrated a significant coupling between the two:

ID was present in 35% of women. Age and BMI were comparable between both groups. In the ID group, the prevalence of TAI and SCH was significantly higher, compared with that in the non-ID group (10% vs 6% and 20% vs 16% respectively). Ferritin was inversely correlated with serum TSH and positive with FT4 levels. In the logistic regression model, ID remained associated with TAI after correction for confounding factors. The association with SCH was absent after correction for the confounders in the logistic regression model, but remained present in the linear regression model.”

MedscapeMedscape Medical News comments on these findings:

“While previous studies have indicated that iron deficiency during pregnancy can affect from 24% to 44% of women, this is the first to show the secondary effect of an increased prevalence of thyroid autoimmunity.”

Thyroid autoimmunity poses serious maternal and fetal risks. Also stated in Medscape:

“Senior author Kris G Poppe, MD, PhD, head of the Endocrine Clinic, University Hospital CHU St-Pierre, Brussels, Belgium, told Medscape Medical News that this finding is important because thyroid autoimmunity in pregnant women increases the risk of miscarriage, preterm delivery, and low birth weight compared with unaffected women.”

For important points on the multiple adverse affects of thyroid autoimmunity on pregnancy and the neonate see the earlier post Subclinical hypothyroidism in pregnancy. Standard of care for pregnancy planning and management should always include testing ferritin, thyroid antibodies and function.

The authors conclude:

ID was frequent during the first trimester of pregnancy and was associated with a higher prevalence of TAI, higher serum TSH, and lower FT4levels.”

Subclinical hypothyroidism in pregnancy

BMJ 349.7978Subclinical hypothyroidism, poor thyroid effect with thyroxine (T4) in the ‘normal’ range and thyrotropin (TSH) within ‘normal’ according to reference ranges of many labs, is a vital issue for both mother and baby. A ‘state of the art review‘ just published in BMJ (British Medical Journal) offers practitioners important reminders guidelines for subclinical hypothyroidism in pregnancy, a common and vital problem. The authors note:

“Subclinical hypothyroidism is associated with multiple adverse outcomes in the mother and fetus, including spontaneous abortion, pre-eclampsia, gestational hypertension, gestational diabetes, preterm delivery, and decreased IQ in the offspring.”

Defining subclinical hypothyroidism

These values of TSH (thyrotropin) are not often flagged as out of range by clinical laboratories:

“Subclinical hypothyroidism is defined as raised thyrotropin combined with a normal serum free thyroxine level. The normal range of thyrotropin varies according to geographic region and ethnic background…These discrepancies are probably the result of different daily intakes of iodine, varying prevalence of thyroid autoimmunity, genetic background, and environmental factors... In the absence of local normative data, the recommended upper limit of thyrotropin in the first trimester of pregnancy is 2.5 mIU/L, and 3.0 mIU/L in the second and third trimester.”

Special physiology of pregnancy

Pregnancy puts weighty demands on thyroid physiology:

“Pregnancy is a stress test for the thyroid. The thyroid gland must produce 50% more thyroid hormone for euthyroidism to be maintained and to provide enough thyroid hormone for the developing fetus. Simultaneously, the physiological changes that accompany pregnancy result in marked alterations in the normal range of thyroid function. Specifically, human chorionic gonadotropin, which peaks in the first trimester, crossreacts with the thyrotropin receptor, resulting in an upper limit of normal of thyrotropin of 2.5 mIU/L during the first trimester.

Causes of subclinical hypothyroidism

As noted in many reports here, by far the most common cause of hypothyroidism in developed countries is autoimmune thyroiditis (Hashimoto’s disease). The authors articulate a number of key points for clinicians to bear in mind:

“The leading cause of hypothyroidism in developing countries is severe iodine deficiency, whereas in developed countries it is autoimmune thyroiditis. Thyroid autoantibodies are detected in about half of pregnant women with subclinical hypothyroidism and in more than 80% with overt hypothyroidism. Antibodies directed against thyroid peroxidase (TPO-Ab) should therefore be measured in patients with subclinical hypothyroidism to establish a diagnosis of autoimmune thyroid disease.”

Personally I have found in practice that antibodies to thyroglobulin (TG-Ab) can crop up and should be measured as well:

“Although only positive TPO-Ab tests have been shown to be significantly associated with hypothyroidism, antibodies to thyroglobulin (TG-Ab) should also be measured. In a study of 992 unselected women who consulted a tertiary referral center for infertility, the overall prevalence of autoimmune thyroid disease was 16%. Of these women, 8% had both antibodies, 5% had TG-Ab only, and 4% had TPO-Ab only. Women with isolated TG-Ab had significantly higher serum thyrotropin concentrations than those without autoimmune thyroid disease…If thyrotropin concentrations are raised, TPO-Ab should be measured to establish a diagnosis of autoimmune thyroid disease. If TPO-Ab are present, the measurement of TG-Ab should be considered.”

Antibodies can be suppressed and might not show up when first measured

It is of great importance for clinicians to be aware that the results of any medical test involving antibodies may be obscured by any one of a number of factors that can suppress antibody expression. This includes pregnancy:

“Finally, it is important to realize that because the immune system is suppressed during pregnancy, thyroid antibody titers decrease on average by 60% in the second half of pregnancy. Consequently, in some women with autoimmune thyroid disease, thyroid antibody test will be negative during pregnancy but positive postpartum because the immunosuppression of pregnancy yields to an immunologic rebound during the first six months postpartum.”

Iodine deficiency during pregnancy

Although autoimmune thyroiditis accounts for most cases of hypothyroid in developed controls in general, there is a greater need for iodine during pregnancy that more easily result in deficiency.

During pregnancy, the iodine requirement increases by about 50% because the woman needs to produce more thyroid hormone, renal loss of iodine is exacerbated by the increased glomerular filtration rate, and the fetus needs to produce thyroid hormone during the second half of pregnancy. The contribution of iodine deficiency to thyroid insufficiency depends on the severity of iodine deficiency, and inadequate iodine intake is seen in both developing and developed countries.In 2011, nearly 45% of Europeans, including pregnant women and those of child bearing age, were estimated to be iodine deficient…The National Health and Nutrition Examination Survey (NHANES) has documented a marked decrease in the median urinary iodine concentration over the past three decades, with the current value for pregnant women being 125 μg/L, indicating that pregnant women in the US are probably mildly iodine deficient.”

There are serious consequences of maternal iodine sufficiency for fetal brain development:

“The Avon Longitudinal Study of Parents and Children confirmed the central role that maternal iodine status plays in the development of childhood cognition…The results showed that after adjustment for confounders, children of women with an iodine to creatinine ratio less than 150 μg/g were more likely to have scores in the lowest quartile for verbal IQ, reading accuracy, and reading comprehension than children of mothers with ratios 150 μg/g or more. Moreover, when the less than 150 μg/g group was subdivided, scores worsened progressively in the less than 150 μg/g, 50-150 μg/g, and less than 50 μg/g subgroups.”

Clinical Note: Care must be taken in prescribing iodine supplementation because inappropriate amounts can trigger autoimmune thryoiditis in those who are vulnerable. See earlier posts on the accepted method for determining iodine deficiency (24 hour urine collection) and other studies pertinent to supplementation by typing ‘iodine’ in the search box above.

Screening for subclinical hypothyroidism in pregnancy

The authors support a rational approach to screening:

“Current evidence on subclinical hypothyroidism does not support universal screening. However, the incidence and impact of overt hypothyroidism and the ability of treatment to prevent associated adverse events is sufficient to justify universal screening for thyroid disease. In support of this position, a cost effective analysis showed that universal screening with the goal of identifying and treating overt hypothyroidism is cost effective. Because universal screening would also identify patients with subclinical hypothyroidism, these patients should be treated as indicated in current guidelines unless ongoing and future studies prove otherwise.”

Clinicians sharing patient care should note:

“…obstetricians and gynecologists provide the majority of pregnancy related care. Studies have reported that some obstetricians have limited knowledge about the association between thyroid disease and pregnancy.”

Treatment for subclinical hypothyroidism in pregnancy

Far too many women and their children currently still fall though the medical cracks. It should be remembered that subclinical hypothyroidism in the first trimester can worsen as the pregnancy progresses. The authors advance the following guidelines:

Subclinical hypothyroidism has been associated with multiple adverse maternal, fetal, and neonatal outcomes, and a preliminary intervention trial suggests that treatment is beneficial. On the basis of current evidence, we believe it is reasonable to recommend treating women with new onset subclinical hypothyroidism during pregnancy. Levothyroxine therapy during pregnancy is inexpensive and has been shown to be safe…Irrespective of the prepregnancy thyrotropin value, all patients should be instructed to have thyrotropin measured as soon as pregnancy is confirmed.”

Treatment algorithm for levothyroxine before pregnancyThe authors conclude with some important points:

“The past two decades have seen major advances in our understanding of the physiological changes that occur in the thyroid during pregnancy and the impact of subclinical hypothyroidism on adverse maternal and fetal outcomes. The normal upper range of thyrotropin is 2.5 mIU/L in the first trimester of pregnancy and 3.0 mIU/L in the second and third trimesters. Hypothyroidism is present in 2-15% of pregnant women. It is mainly caused by iodine deficiency in developing countries and autoimmune thyroid disease in developed countries. Subclinical hypothyroidism has been associated with multiple negative outcomes, including pregnancy loss, preterm delivery, gestational diabetes, and impaired neurologic development in the offspring. Women on levothyroxine before conception require careful management to ensure that the euthyroid state is maintained throughout pregnancy. “

Schizophrenia risk increased by maternal inflammation

American Journal of PsychiatrySchizophrenia is well recognized to have a neuroinflammatory component, and a study just published in the American Journal of Psychiatry links maternal inflammation during pregnancy as reflected in elevated CRP (C-reactive protein) levels with a markedly increased irisk of schizophrenia in offspring. The authors state:

“The objective of the present study was to investigate an association between early gestational C-reactive protein, an established inflammatory biomarker, prospectively assayed in maternal sera, and schizophrenia in a large, national birth cohort with an extensive serum biobank.”

They examined the maternal sera of 777 schizophrenia cases for C-reactive protein in comparison to 777 matched control subjects. The correlation was striking:

“Increasing maternal C-reactive protein levelswere significantly associated with schizophrenia in offspring. This finding remained significant after adjusting for potential confounders, including maternal and parental history of psychiatric disorders, twin/singleton birth, urbanicity, province of birth, and maternal socioeconomic status.”

A reviewer in Medscape Family Medicine notes:

“A growing body of epidemiologic and preclinical evidence suggests that infection and subsequent immune activation play a role in the etiology of schizophrenia, the researchers note.”

Also noted in Medscape Family Medicine:

  • “Overall, the median maternal C-reactive protein level for case patients was 2.47 mg/L. The median level for control individuals was 2.17 mg/L.
  • The investigators found that for every 1 mg/L increase in maternal C-reactive protein, the risk for schizophrenia was increased by 28%.
  • The investigators speculate that “maternal inflammation during pregnancy may ‘prime’ the brain to broadly increase the risk for the later development of different types of psychiatric syndromes.”
  • They note that their previous research in this same Finnish national birth cohort “demonstrated a significant increase in maternal C-reactive protein levels in pregnancies that gave rise to childhood autism.”

Authors of an accompanying editorial note:

“Firstly, while the authors only assessed C-reactive protein, proinflammatory markers, such as interleukin 8 and tumor necrosis factor alpha, have been shown to have similar associations in other birth cohorts. This suggests that the risk is associated with a generally elevated inflammatory state. Secondly, the inflammation story does not appear to be specific to schizophrenia because elevated markers of inflammation are also found in association with depression, with posttraumatic stress disorder, and in many physical diseases Indeed, Brown and his research group have also reported elevated levels of maternal C-reactive protein in association with autism…The inflammatory system and the hypothalamic-pituitary-adrenal (HPA) axis, which mediates the stress response, are inextricably linked: cytokines can elicit a stress response through activation of the fetal HPA axis, and stressors can lead to HPA axis dysregulation and loss of normal glucocorticoid-associated anti-inflammatory tone. Cotter and Pariante previously proposed that many of the neuropathological features observed in schizophrenia are in keeping with nonspecific glucocorticoid-related brain changes. Autoimmunity may also underlie some of the elevation in inflammatory tone seen in people with schizophrenia, and a bidirectional association between schizophrenia and autoimmune disorders has been reported. The recent upsurge of interest in anti-N-methyl-d-aspartic acid receptor encephalitis as a differential diagnosis for schizophrenia demonstrates the importance of autoimmunity in psychosis.”

The authors of the primary paper conclude:

“This finding provides the most robust evidence to date that maternal inflammation may play a significant role in schizophrenia, with possible implications for identifying preventive strategies and pathogenic mechanisms in schizophrenia and other neurodevelopmental disorders.”

Infection and Autoimmunity

BMJ Open Clinicians who undertake case management of autoimmunity that latent autoimmune conditions are often triggered by for which there are scores of examples. In this context it’s edifying to consider another just-published study in BMJ (British Medical Journal) Open examining infection as a trigger for rheumatoid arthritis:

“We observed a marked increase in overall infections at the time of RA onset, and signs of a defective antibacterial defence mechanism, contrasting with fewer infections in the late RA stage…The model is supported by evidence indicating that monocytes and macrophages as well as other cytokine-producing cell types, are key players in RA, and by more recent reports of non-specific and sustained immunostimulation during RA development…It can be speculated that frequent early infections initiate a compensatory immune hyper-reactivity which reduces the infection load while stimulating the development of RA in predisposed individuals.”

Clinical note: “…in predisposed individuals” is a critical point. Practitioners should be adept in comprehensively assessing the various potential underlying contributing causes that predispose to loss of immune tolerance.

Histamine intolerance

American Journal of Clinical NutritionHistamine intolerance (HI), which may present with a multitude of potential symptoms, occurs when the capacity to degrade histamine falls short. It can contribute numerous diverse conditions including IBS and inflammatory bowel diseases, asthma, postural orthostatic tachycardia syndrome (POTS), complications of pregnancy, drug hypersensitivity, headache, cardiac arrhythmia, blood pressure dysregulation, and intestinal permeability (by means of which it contributes to autoimmunity). Suspicion of HI should be high if relevant symptoms persist after antibody mediated food allergies are avoided or ruled out. A paper published in The American Journal of Clinical Nutrition expands on key points of histamine intolerance, a phenomenon that may be far more widespread than generally recognized.

“Histamine belongs to the biogenic amines and is synthesized by…mast cells, basophils, platelets, histaminergic neurons, and enterochromaffine cells, where it is stored intracellularly in vesicles and released on stimulation. Histamine is a potent mediator of numerous biologic reactions.”

Histamine intolerance widely unrecognized in clinical practice:

Because of the multifaceted symptoms, the existence of histamine intolerance is frequently underestimated, or its symptoms are misinterpreted. Clinical symptoms and their provocation by certain foods and beverages appear similar in different diseases, such as food allergy and intolerance of sulfites, histamine, or other biogenic amines (eg, tyramine). Therefore, the differentiation of the causal agent in adverse reactions to food, alcohol, and drugs is a difficult challenge.”

There are numerous ways to incite the release of histamine…

“Besides the well-known triggering of degranulation of mast cells by crosslinking of the FcεRI receptor by specific allergens, several other nonimmunologic stimuli, such as neuropeptides, complement factors (ie, C3a and C5a), cytokines, hyperosmolarity, lipoproteins, adenosine, superoxidases, hypoxia, chemical and physical factors (eg, extreme temperatures, traumas), or alcohol and certain food and drugs, may activate mast cells.”

In other words, stimuli as diverse as temperature, dehydration and mechanical trauma to Histamine and histamine intolerancelipoproteins, oxidative stress, reduced oxygen saturation, various signalling molecules and alcohol of any kind, not to mention food and drugs, can trigger the release of histamine from mast cells. The vast range of potential symptoms is congruent with its mechanisms of action:

“It causes smooth muscle cell contraction, vasodilatation, increased vascular permeability and mucus secretion, tachycardia, alterations of blood pressure, and arrhythmias, and it stimulates gastric acid secretion and nociceptive nerve fibers. In addition, histamine has been known to play various roles in neurotransmission, immunomodulation, hematopoiesis, wound healing, day-night rhythm, and the regulation of histamine- and polyamine-induced cell proliferation and angiogenesis in tumor models and intestinal ischemia.”

Histamine intolerance occurs when the capacity to degrade histamine is insufficient.

“Histamine intolerance results from a disequilibrium of accumulated histamine and the capacity for histamine degradation. The main enzyme for metabolism of ingested histamine is diamine oxidase (DAO). An impaired histamine degradation based on a reduced DAO activity and the resulting excess of histamine may cause numerous symptoms mimicking an allergic reaction….In histamine-sensitive patients with reduced DAO activity, symptoms occur even after the ingestion of the small amounts of histamine that are well tolerated by healthy persons. Symptoms can be manifest via…actions of histamine in multiple organs, such as the gastrointestinum, lung, skin, cardiovascular system, and brain, according to the expression of histamine receptors.”

Patients with chronic headaches should be investigated for histamine intolerance:

Headache can be induced dose-dependently by histamine in healthy persons as well as in patients with migraine….In migraine patients, plasma histamine concentrations have been shown to be elevated both during headache attacks and during symptom-free periods. An increase in the number of brain mast cells is associated with pathologic conditions such as migraine, cluster headache, and multiple sclerosis. Many migraine patients have histamine intolerance evidenced by reduced DAO activity.”

It can play a major role in gastrointestinal disorders:

“…gastrointestinal ailments including diffuse stomach ache, colic, flatulence, and diarrhea are leading symptoms of histamine intolerance. Elevated histamine concentrations and diminished DAO activities have been shown for various inflammatory and neoplastic diseases such as Crohn disease, ulcerative colitis, allergic enteropathy, food allergy, and colorectal neoplasmas. In the colonic mucosa of patients with food allergy, a concomitant reduced HNMT and an impaired total histamine degradation capacity (THDC) have been found, so that the enzymes cannot compensate each other. Therefore, an impaired histamine metabolism has been suggested to play a role in the pathogenesis of these diseases.”

Chronic nasal congestion and asthma are considerations:

“During or immediately after the ingestion of histamine-rich food or alcohol, rhinorrea or nasal obstruction may occur in patients with histamine intolerance; in extreme cases, asthma attacks also may occur. Reduced HNMT activity has been shown for patients with food allergy and asthma bronchiale.”

Dysmenorrhea, estrogen dominance and menstrual headache should be evaluated for histamine intolerance:

“In the female genital tract, histamine is mainly produced by mast cells, endothelial cells, and epithelial cells in the uterus and ovaries. Histamine-intolerant women often suffer from headache that is dependent on their menstrual cycle and from dysmenorrhea. Besides the conctractile action of histamine, these symptoms may be explained by the interplay of histamine and hormones. Histamine has been shown to stimulate, in a dose-dependent manner, the synthesis of estradiol via H1R; meanwhile, only a moderate effect on progesterone synthesis was observed. The painful uterine contractions of primary dysmenorrhea are mainly caused by an increased mucosal production of prostaglandine F2α stimulated by estradiol and attenuated by progesterone. Thus, histamine may augment dysmenorrhea by increasing estrogen concentrations. And, in reverse, estrogen can influence histamine action. A significant increase in weal and flare size in response to histamine has been observed to correspond to ovulation and peak estrogen concentrations. In pregnancy, DAO is produced at very high concentrations by the placenta, and its concentration may become 500 times that when the woman is not pregnant. This increased DAO production in pregnant women may be the reason why, in women with food intolerance, remissions frequently occur during pregnancy.”

Why might someone develop histamine intolerance?

“Histamine intolerance can develop through both increased availability of histamine and impaired histamine degradation. Underlying conditions for increased availability may be an endogenous histamine overproduction caused by allergies, mastocytosis, bacterias, gastrointestinal bleeding, or increased exogenous ingestion of histidine or histamine by food or alcohol. Other biogenic amines, such as putrescine, may also be involved in displacing histamine from its mucosal mucine linkage, which results in an increase of free absorbable histamine in circulation. However, the main cause of histamine intolerance is an impaired enzymatic histamine degradation caused by genetic or acquired impairment of the enzymatic function of DAO or HNMT. Gastrointestinal diseases with altered enterocytes also may cause decreased production of DAO. Yet another cause can be competitive inhibition of histamine degradation of DAO by other biogenic amines, alcohol, or drugs…DAO inhibits the transepithelial permeation of exogenous histamine, and impaired DAO activity results in increased enteral histamine uptake with consequent increased plasma histamine concentrations and corresponding symptoms. Increased amounts of histamine metabolites may also inhibit HNMT, the second enzyme metabolizing histamine.”

There is evidence for genetic in some patients but the role of chronic inflammation appears to take center stage:

“Recently, a potential genetic background of a reduced histamine metabolism has also been investigated… Various single-nucleotide polymorphisms (SNPs) in the DAO gene have been shown to be associated with inflammatory and neoplastic gastrointestinal diseases, such as food allergy, gluten-sensitive enteropathy, Crohn disease, ulcerative colitis, and colon adenoma. No significant difference in the distribution of the investigated HNMT alleles could be shown between patients with gastrointestinal diseases and control subjects, but a functional relevant polymorphism of the HNMT gene (chromosome 2q22) has been described for white asthma patients. Conversely, this association could not be observed in Japanese, German pediatric, and East Indian populations. Thus, histamine intolerance seems to be acquired mostly through the impairment of DAO activity caused by gastrointestinal diseases or through the inhibition of DAO, but the high interindividual variations in the expression of DAO in the gut and the association of SNPs in the DAO gene with gastrointestinal diseases provide evidence for a genetic predisposition in a subgroup of patients with histamine intolerance.”

Regarding the amount of histamine consumed:

In contrast to an IgE–mediated food allergy, in which the ingestion of even a small amount of the allergen elicits symptoms, in histamine intolerance, the cumulative amount of histamine is crucial. Besides variations in the amount of histamine in food according to storage and maturation, the quantity consumed, the presence of other biogenic amines, and the additional intake of alcohol or DAO-blocking drugs are pivotal factors in the tolerance of the ingested food.”

See Foods rich in histamine and Foods with suggested histamine-releasing capabilities. Regarding alcohol in general and wine in particular:

Alcohol, especially red wine, is rich in histamine and is a potent inhibitor of DAO. The relation between the ingestion of wine, an increase in plasma histamine, and the occurrence of sneezing, flushing, headache, asthma attacks, and other anaphylactoid reactions and a reduction of symptoms by antihistamines has been shown in various studies.”

Sulfite sensitivity can be mistaken for histamine intolerance:

“Sulfites may be contained in wine, but they are also contained in foods that are poor in histamine, such as fruit juice, frozen vegetables, and lettuce. Thus, in patients reporting intolerance to wine, a careful history of reactions to other foods rich in histamine or sulfites should be taken.”

And the reaction to wine is not necessarily determined by the amount of histamine present:

“In DBPC wine tests with healthy persons and in patients with chronic urticaria and wine intolerance, the histamine content did not influence wine tolerance. In the latter group, an increase in plasma histamine could be shown, paradoxically, after ingestion of the histamine-poor wine.”

Clinicians attempting to diagnose histamine intolerance should bear in mind that it can be tricky to judge it by foods consumed:

“…the amount of histamine in natural food varies pronouncedly according to storage and maturation.”

See also Drugs releasing histamine or inhibiting diamine oxidase. Regarding laboratory assessment of histamine intolerance:

“In a patient with clinical suspicion of histamine intolerance (ie, ≥2 typical symptoms), improvement of symptoms by histamine-free diet or antihistamines, DAO may be determined in serum or tissue biopsy… Furthermore, the total histamine degradation capacity [by DAO] can be measured… Serum DAO concentrations showed no significant daily variations and no significant sex differences…. Histamine intolerance is presumably highly likely in patients with DAO activity <3 U/mL, likely (but less likely) in patients with DAO activity <10 U/mL, and improbable in patients with DAO activity ≥10 U/mL.”

The authors conclude:

“In patients with typical symptoms of histamine intolerance that are triggered by histamine-rich food and alcohol, with intolerance of drugs that liberate histamine or block DAO, and with a negative diagnosis of allergy or internal disorders, histamine intolerance should be considered. A histamine-free diet, if necessary, supported by antihistamines or the substitution of DAO, leads to an improvement of symptoms…”


Neurogastroenterology & MotilityIt should be clear that histamine intolerance can be a cause of IBS (irritable bowel syndrome), as evidenced by a study published in the journal Neurogastroenterology & Motility in which the authors observed the effects of histamine release on bowel ANS (autonomic nervous system) function:

“We hypothesized that blockade of histamine H1 receptors affects ANS responses differently between IBS subjects and controls.”

They subjected twelve individuals with IBS and the same number of matched controls to irritation of the bowel by either chlorphenamine or the same amount of saline (sham), and with stimulated their rectums with electrical currents of 0 mA (for the sham) or 30 mA. They quantified autonomic nervous system function with heart rate variability (HRV) and mean arterial pressure (MAP), and measured plasma catecholamines and histamine. They also recorded subjective perceived stress during this mildly barbarous trial. Blocking histamine receptors with chlorphenamine made a big difference:

“Mean arterial pressure showed significant effects of diagnosis and drug × diagnosis interaction. The MAP significantly increased after chlorphenamine administration in IBS subjects, but not in controls. Heart rate revealed a significant drug effect, which decreased after chlorphenamine administration in controls, but not in IBS subjects. Perceived stress significantly increased by rectal stimulation and a significant stimulus × diagnosis interaction was revealed, indicating greater reduction in IBS subjects by chlorphenamine.”

They concluded that histamine plays a significant role in gut autonomic dysregulation of IBS patients:

“Sympathetic vasomotor tone in IBS subjects differentially responded on administration of a histamine H1 antagonist to that of controls. These findings suggest an increased histaminergic activity in IBS subjects.”


GastroenterologyThe authors of a study published in Gastroenterology also correlated the effect of the release of mast cell mediators (histamine) proximal to nerve fibers in gut mucosa on pain in IBS:

“We assessed colonic mast cell infiltration, mediator release, and spatial interactions with mucosal innervation and their correlation with abdominal pain in IBS patients.”

They quantified pain in IBS patients, identified colonic mucosal mast cells and measured their tryptase and histamine release. They also assessed intestinal nerve to mast cell distance with electron microscopy…

“Thirty-four out of 44 IBS patients (77%) showed an increased area of mucosa occupied by mast cells as compared with controls. There was a 150% increase in the number of degranulating mast cells. Mucosal content of tryptase was increased in IBS and mast cells spontaneously released more tryptase and histamine. Mast cells located within 5 μm of nerve fibers were 7.14 ± 3.87/field vs. 2.27 ± 1.63/field in IBS vs. controls. Only mast cells in close proximity to nerves were significantly correlated with severity and frequency of abdominal pain/discomfort.”

In other words, mast cells releasing histamine close to nerve cells in the colon correlated with IBS pain.


Hypertension Vol 45 Issue 2Clinicians should also be aware that histamine release due to mast cell activation (MCA) can cause Postural Orthostatic Tachycardia Syndrome (POTS; also called Postural Tachycardia Syndrome) as described by a fascinating paper published in the journal Hypertension.

Postural tachycardia syndrome (POTS) is a disabling condition…characterized by symptoms of fatigue, tachycardia, shortness of breath, and even syncope on standing. The etiology is not clear, but 2 possibilities have been proposed previously. In the neuropathic variant, the primary defect is thought to be a partial autonomic denervation that compromises lower limbs with exaggerated orthostatic venous pooling, and perhaps the kidneys with low levels of plasma renin activity. Patients with the hyperadrenergic variant are thought to have centrally driven sympathetic activationA circulating vasodilator could produce reflex sympathetic activation, presenting clinically as “hyperadrenergic” POTS. In our evaluation of patients with POTS, some described flushing episodes associated with orthostatic intolerance. On the basis of this observation, also reported by others, we hypothesized that activated mast cells may provide a source of circulating vasodilators in a subset of patients with hyperadrenergic POTS. If true, histamine and other mast cell mediators could play an important role in the pathogenesis of this syndrome.”

The authors describe the phenomenon of mast cell activation (MCA):

“In 1991, Roberts and Oates described the clinical syndrome of idiopathic mast cell activation (MCA). In this condition, there is no evidence of mast cell proliferation, but patients are disabled by episodic MCA, documented by accumulation of mediators in plasma or urine. Patients with this syndrome typically present episodes or “attacks” of flushing accompanied by palpitations, lightheadedness, dizziness, shortness of breath, occasional nausea and diarrhea, headache, and syncope. Here we describe patients disabled by persistent orthostatic intolerance and evidence of MCA. These patients often present with a typical hyperadrenergic variant of POTS and biochemical evidence of MCA.”

Their data confirmed the role of histamine in POTS:Mechanisms underlying association between MCA and hyperadrenergic POTS

MCA+POTS patients were characterized by episodes of flushing, shortness of breath, headache, lightheadedness, excessive diuresis, and gastrointestinal symptoms such as diarrhea, nausea, and vomiting. Triggering events include long-term standing, exercise, premenstrual cycle, meals, and sexual intercourse. In addition, patients were disabled by orthostatic intolerance and a characteristic hyperadrenergic response to posture, with orthostatic tachycardia (from 79±4 to 114±6 bpm), increased systolic blood pressure on standing (from 117±5 to 126±7 mm Hg versus no change in POTS controls), increased systolic blood pressure at the end of phase II of the Valsalva maneuver (157±12 versus 117±9 in normal controls and 119±7 mm Hg in POTS), and an exaggerated phase IV blood pressure overshoot (50±10 versus 17±3 mm Hg in normal controls)… Episodes of MCA were documented in these patients by elevated levels of urinary methylhistamine taken immediately after a spontaneous event… The symptoms described during these spells are probably induced by acute release of mast cell mediators such as histamine and PGD2. Patients with isolated MCA are symptomatic only during episodes, whereas our group of patients also experienced chronic fatigue and orthostatic intolerance in between episodes, eventually leading to a disabling condition.”

Clinicians managing POTS should note the authors’ conclusion:

“We report a novel syndrome of chronic hyperadrenergic orthostatic intolerance associated with episodes of MCA… A correct diagnosis is important because the presence of MCA mandates a different approach in the treatment of these patients. β-Blockers, a commonly used therapeutic option in POTS patients, should be used with caution, if at all, because of the risk of triggering MCA. These patients can be treated with H1/H2 histamine antagonist and central sympatholytics.”


Annals of DermatologyRegarding atopic dermatitis (AD) and histamine intolerance, a typical case is described by the authors of a paper published in Annals of Dermatology. Their findings compel them to conclude:

In cases of AD showing negative results on allergy tests and worsening of AD skin lesions after intake of certain types of food, it would be reasonable to consider histamine intolerance. Therefore, a low-histamine diet and a histamine-free diet could be helpful for such cases.”


Inflammatory Bowel Diseases Vol 17 Issue 2From a realistic clinical perspective the histamine-degrading enzyme DAO (diamine oxidase) takes center stage. In illuminating research published in the journal Inflammatory Bowel Diseases the authors investigated the measurement of serum DAO activity in inflammatory bowel disease (Crohn’s disease and ulcerative colitis) and its correspondence to intestinal permeability was published in the journal Inflammatory Bowel Diseases. The authors note:

“The intestinal mucosa serves as a major anatomic and functional barrier to potentially harmful intraluminal components such as bacteria and several antigens. The intestinal barrier is formed by epithelial cells and the junctional complex, including the tight junction (TJ) complex. Alterations of the composition of TJs was reported for both Crohn’s disease (CD) and ulcerative colitis (UC)… In addition, the impaired permeability may represent the early onset of inflammatory bowel disease (IBD) because increased intestinal epithelial permeability precedes clinical relapse in patients with asymptomatic CD… These data suggest that small intestinal permeability plays a critical role in the disease onset of IBD and an examination of small intestinal permeability would be useful for diagnosing IBD and predicting disease relapse.”

Regarding intestinal permeability and diamine oxidase activity:

Diamine oxidase (DAO) is an enzyme that catalyzes the oxidation of diamines such as histamine, putrescine, and cadaverine. In humans and rodents, DAO is specifically located at the apical end of mature villous cells with high activity and its activity reflects the integrity and maturity of the small intestinal mucosa. Several studies of humans and animals revealed that DAO activity in serum inversely correlates with intestinal permeability of small intestine… We measured serum DAO activity levels in patients with IBD and evaluated the clinical significance of DAO in IBD.”

Their results show a strong correlation of DAO activity and IBD regardless of whether the condition is in an acute symptomatic or latent phase, and whether or not CRP or white blood cells are elevated:

Serum DAO activity in patients with CD was significantly lower than that in control subjects. In addition, serum DAO activity in patients with UC was significantly lower than that in control subjects. There were no significant differences between patients with active CD and inactive CD ( or in patients with active UC and inactive UC. Furthermore, the disease phenotype of CD and UC was not associated with serum DAO activity. Serum DAO activity was not significantly correlated with CRP or WBC.”

And a great insight into the pathogenesis of ulcerative colitis (UC) emerges:

“This study first demonstrates that serum DAO activity is significantly lower in patients with CD and UC regardless of the level of disease activity. Of note, in patients with UC in whom small intestinal inflammation was not involved, serum DAO activity was significantly lower than that in healthy controls. These findings strongly indicate that small intestinal permeability is strongly involved in the pathophysiology of not only CD but also UC.”

The authors conclude:

“In conclusion, measurement of serum DAO activity can be an easy and convenient modality for evaluating small intestinal permeability. Reduced serum DAO activity in patients with IBD suggests the importance of mucosal permeability of the small intestine as a pathogenic factor and its measurement together with serology, clinical factors, and genetics might be useful for predicting the disease onset of IBD.”


Human Reproduction Update Vol 14 Issue 5Histamine intolerance and diamine oxidase activity are also very relevant in pregnancy. In a paper published in Human Reproduction Update the authors note:

The balance between histamine and the histamine-degrading enzyme DAO seems to be crucial for an uncomplicated course of pregnancy. Reduced or precipitously falling DAO activities have been found in high-risk pregnancies, whereas maternal plasma enzyme titres within the normal range have been mostly associated with a favourable fetal prognosis. DAO at the feto–maternal interface has therefore been supposed to act as a metabolic barrier to prevent excessive entry of bioactive histamine from the placenta into the maternal or fetal circulation.”

Effects of histamine and diamine oxidase activities on pregnancyThey undertook a detailed and extensive review of the voluminous literature on histamine and pregnancy, finding…

“Without the protective action of an increased DAO activity, an excess of histamine exerts pathological effects on the course of pregnancy. The presence of the HRs [histamine receptors] at the feto–maternal interface also support the view that prolonged exposure of feto–maternal interface tissues to high levels of histamine might have fundamental roles in the pathogenesis of pre-eclampsia…Persistently low or falling DAO plasma curves have been shown in various pregnancies complications such as toxaemia, diabetes, anaemia, threatened and missed abortion compared with normal pregnancies, especially during the last trimester. Fetal organic and skeletal abnormalities as far as spontaneous abortion after DAO inhibition with aminoguanidine observed in pregnant rats stress the impact of a sufficient histamine degradation during pregnancy.”

On the therapeutic side practitioners can consider DAO support as an option when low DAO activity is determined:

“Moreover, a substitution of DAO might present a therapeutical option for patients with high-risk pregnancy or women with yet-to be identified genetically predetermined defects in DAO activity in the future.”


Wiener klinische Wochenschrift Vol 125 Iss 9-10Regarding the laboratory diagnosis of histamine intolerance, the authors of a paper recently published in Wiener klinische Wochenschrift (Viennese Clinical Weekly—The Central European Journal of Medicine) examine the usefulness of serum diamine oxidase activity, noting…

“Histamine intolerance (HIT) is characterized by an imbalance between histamine intake and the capacity for histamine degradation. The main enzyme for metabolizing ingested histamine is diamine oxidase (DAO). Determining DAO activity in serum may be useful in diagnosing HIT.”

They assessed 316 subjects with clinically suspected HIT and 55 healthy controls for serum DAO activity over three and a half years. Twenty of those with highly reduced DAO activity went on a histamine-free diet for six to twelve months and their DAO activity was determined again. The serum DAO activity had high clinical significance:

We found that DAO activity was significantly lower in patients than in healthy control subjects. Furthermore, 54 patients had highly reduced serum DAO activity (< 40 HDU/ml). Their main symptoms involved the skin, gastrointestinal tract, respiratory system, and eyes. In all the 20 patients with highly reduced DAO activity, the main clinical symptoms typical of histamine intolerance disappeared after they adopted a histamine-free diet. Furthermore, the serum DAO activity values measured increased significantly.

Their conclusion of their study is a straightforward endorsement of serum DAO activity for evaluating HI (HIT):

“Our results suggest that determining DAO activity in serum is a useful tool in diagnosing HIT. Furthermore, our results showed the benefit of a histamine-free diet because after the diet the majority of symptoms disappeared and the serum DAO activity significantly increased.”


Pediatric ResearchSerum DAO activity applies just as well to case management of pediatric gastroenteritis as evidenced by a study in the journal Pediatric Research. According to these findings, DAO activity also reflected number of functioning enterocytes (intestinal cells):

“Patients with severe gastroenteritis tended to have lower DAO activity values than patients with moderate gastroenteritis. Our results support the hypothesis that serum DAO activity is a marker of the total mass of functional enterocytes, the decrease of which during gastroenteritis is reflected in a decrease of serum DAO activity values.”


PLOS ONEInterestingly, diamine oxidase is also involved in hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) in particular and drug hypersensitivity in general, a widespread clinical problem. The authors of study published in PLOS One state:

“Non-steroidal anti-inflammatory drugs (NSAIDs) are the drugs most frequently involved in hypersensitivity drug reactions… Unpredictable adverse drug reactions related to NSAIDs are common in clinical practice… It is intriguing that chemically unrelated NSAIDs and NSAIDs with different pharmacological mechanisms cause cross-hypersensitivityHistamine is released in the allergic response to NSAIDs and is responsible for some of the clinical symptoms. The aim of this study is to analyze clinical association of functional polymorphisms in the genes coding for enzymes involved in histamine homeostasis with hypersensitivity response to NSAIDs.”

They analyzed single nucleotide polymorophisms (SNPs) relevant to histamine metabolism and DAO in 442 subjects with NSAID hypersensitivity and 414 healthy matched controls. Their data did indeed show a correspondence between DAO capacity and hypersensitivity to NSAIDs:

The detrimental DAO 16 Met allele (rs10156191), which causes decreased metabolic capacity, is overrepresented among patients with crossed-hypersensitivity to NSAIDs with an OR = 1.7 with a gene-dose effect. The association was replicated in two populations from different geographic areas.”

The authors summarize the great clinical significance of their data:

“In conclusion, the findings described in this study indicate that a detrimental mutation in the DAO gene is related to a clinical development of hypersensitivity to NSAIDs. These findings agree with the general model in which mutations in genes encoding histamine-metabolizing enzymes may increase the risk, or modify the clinical presentation, of allergic diseases in which histamine plays an important role. This finding could guide future research in the area of drug hypersensitivity as it points to a common mechanism which may affect the clinical presentation of hypersensitivity reactions, regardless of drug-specific triggering mechanisms.”


Allergy Vol 66 Issue 7Similar findings were reported in a paper published in the journal Allergy. Here the authors discriminated between the presence of SNPs that impair DAO activity and the actual phenotypic expression of histamine intolerance.

“Histamine intolerance (HIT) is associated with an excess of histamine because of an impaired function of the histamine-degrading enzyme diamine oxidase (DAO)… Diamine oxidase serum activity was significantly associated with seven SNPs within the DAO gene… Diamine oxidase variants were not associated with the HIT phenotype per se, only with DAO activity alone and the subgroup of HIT patients displaying a reduced DAO activity.”

Clinical note: This is a good example for the preference of a functional test (in this case serum DAO activity) over a genetic test in clinical case management. As in so many other conditions, the genes may be there but how are they being expressed? The authors conclude:

DAO gene variants strongly influence DAO expression and activity but alone are not sufficient to fully effectuate the potentially associated disease state of HIT, suggesting an interplay of genetic and environmental factors.”


Inflammation ResearchCould daily variations in serum diamine oxidase confound the attempt to measure and manage histamine intolerance? Happily, this was investigated by research published in the journal Inflammation Research.

“Histamine in food has been shown to induce intolerance reactions mimicking food allergy. These reactions seem to be due to impaired histamine metabolism caused by reduced diamine oxidase activity. To validate routine serum diamine oxidase assessment, daily variations of diamine oxidase were evaluated.”

Examining diamine oxidase activity every two hours from 9 am to 5 pm, the authors found…

Serum diamine oxidase levels showed no significant daily variations and no significant sex differences. Antihistamines had no influence on diamine oxidase activity except for cimetidine, which caused 25% inhibition at the highest dose tested and diphenhydramine, which caused 19% increase of enzyme activity.”


Clinical summary: Histamine intolerance is a widespread phenomenon that can mimic allergy. It plays a role in many diverse conditions including IBS and inflammatory bowel diseases, asthma, postural orthostatic tachycardia syndrome (POTS), complications of pregnancy, drug hypersensitivity, headache, cardiac arrhythmia, blood pressure dysregulation, and intestinal permeability (by means of which it contributes to autoimmunity). Suspicion should be raised if relevant symptoms persist after antibody mediated food intolerance is out of the picture. It can be objectively evaluated with serum DAO activity. HI can be ameliorated by supplementation with DAO. Practitioners need to be astute in its diagnosis and management.

Tune back in for a forthcoming post on histamine intolerance and wine.


ECNPUpdate: Medscape Medical News reports from the 26th European College of Neuropsychopharmacology (ECNP) Congress in Barcelona, Spain that Antihistamine May Decrease Schizophrenia Symptoms. Quoting the authors of the study just presented:

Histamine has received relatively little attention in clinical studies of psychiatric disorders even though it has important functions as a regulator of several key neurotransmitters…Our results suggest that a H2 [histamine] receptor antagonist has antipsychotic properties and may provide a new potential pharmacological approach to the treatment of patients with schizophrenia who have not responded well enough to presently available treatments.”

Autism and autoimmunity: more evidence

Molecular PsychiatryAutism and autoimmunity, mediated by brain-reactive antibodies produced by the mother during pregnancy, is emerging as an important association to bear in mind for prevention and treatment. A study just published in Molecular Psychiatry adds to the evidence that should be known to every practitioner offering support before and during pregnancy:

“It is believed that in utero environmental factors contribute to autism spectrum disorder (ASD). The goal of this study was to demonstrate, using the largest cohort reported so far, that mothers of an ASD child have an elevated frequency of anti-brain antibodies and to assess whether brain reactivity is associated with an autoimmune diathesis of the mother.”

The authors examined the plasma (blood) of 2431 mothers of children with autism and plasma of 653 other women of child-bearing age for anti-brain antibodies. Mothers who had an ASD child were also examined for anti-nuclear antibodies which are associated with numerous other autoimmune disorders. There was a very strong correlation:

Mothers of an ASD child were four times more likely to harbor anti-brain antibodies than unselected women of child-bearing age (10.5 vs 2.6%). A second cohort from The Autism Genetic Resource Exchange with multiplex families displayed an 8.8% prevalence of anti-brain antibodies in the mothers of these families. Fifty-three percent of these mothers with anti-brain antibodies also exhibited anti-nuclear autoantibodies compared with 13.4% of mothers of an ASD child without anti-brain antibodies and 15% of control women of child-bearing age. The analysis of ASD mothers with brain-reactive antibodies also revealed an increased prevalence of autoimmune diseases, especially rheumatoid arthritis and systemic lupus erythematosus.”

Lead investigator Betty Diamond, MD, PhD was quoted in Medscape Medical News:

“This study strongly suggests that maternal antibrain antibodies associate with autism spectrum disorder [ASD] in the child, as others have also shown, and suggest that the presence of antibrain antibodies may be associated with other manifestations of autoimmunity in the mom.”

Quoting also from Medscape Medical News:

“These data are consistent with a predisposition to more generalized autoimmunity in some mothers with anti-brain antibodies who have a child with ASD,” Dr. Diamond and colleagues say. Self-reported autoimmune diseases, especially RA and SLE, were also more common in the mothers of an ASD child with antibrain antibodies…The possibility of autoimmune mechanisms being a contributing factor in ASD has been entertained as early studies suggested that individuals with ASD have a family history of autoimmune disease,” the investigators note. A recent study examining autoimmune disorders in women, with data for more than 600,000 births, showed that women with either RA or celiac disease had an increased risk of having a child with ASD (Atladottir et al, Pediatrics 2009;124:687-694).”

The authors conclude:

“This study provides robust evidence that brain-reactive antibodies are increased in mothers of an ASD child and may be associated with autoimmunity. The current study serves as a benchmark and justification for studying the potential pathogenicity of these antibodies on the developing brain. The detailed characterization of the specificity of these antibodies will provide practical benefits for the management and prevention of this disorder [autism].”

Clinical note: considering how common autoimmunity has become, screening antibodies should be considered for all women planning pregnancy.

Readers interested in this post should also see the earlier Autism and maternal antibodies that attack the fetal brain.

Iodine deficiency, pregnancy, and autoimmunity

 [fvplayer src=’′ width=480 height=270 autoplay=false splash=’’ splashend=show]

Iodine deficiency is still a serious concern, especially for pregnant women in North America, as reported in a review just published in the journal Thyroid. Despite global improvements since 1990, iodine sufficiency has actually been declining in US adults. As the authors state, the consequences can be severe:

Thyroid“Dietary iodine intake is required for the production of thyroid hormone. Consequences of iodine deficiency include goiter, intellectual impairments, growth retardation, neonatal hypothyroidism, and increased pregnancy loss and infant mortality. Thyroid hormone is particularly crucial for fetal and infant neurodevelopment in utero and in early life, and insufficient iodine during pregnancy and infancy results in neurological and psychological deficits in children…Iodine deficiency remains the leading cause of preventable mental retardation worldwide. In adults, mild-to-moderate iodine deficiency increases the incidence of hyperthyroidism due to toxic goiter.”

The authors defined population iodine sufficiency as a median urinary iodine concentrations of 100–299 μg/L in school-aged children and equal to or more than 150 μg/L in pregnant women, with these serious implications for pregnant women and their children in the US:

“Based on National Health and Nutrition Examination Surveys (NHANES), the median UIC in U.S. adults decreased by >50% between the early 1970s and the late 1990s. Of particular concern, the prevalence of UICs <50 μg/L among women of childbearing age increased by almost fourfold, from 4% to 15%, over this period. The most recent NHANES survey (2009–2010) demonstrated that the overall U.S. population remains iodine-sufficient, with a median UIC of 144 μg/L among individuals aged six years and older. However, aggregate NHANES data from 2001 to 2006 showed that U.S. pregnant women sampled were only marginally iodine-sufficient (median UIC, 153 μg/L) and the most recent NHANES data from 2007 to 2010 demonstrated that the median UIC among pregnant U.S. women had dropped to <150 μg/L, indicating mild iodine deficiency.”

Considering possible causes for this growing insufficiency they note…

“Reductions in U.S. dietary iodine over the last several decades have been variously ascribed to a possible reduction in the iodine content of dairy products, the removal of iodate dough conditioners in commercially produced bread, new recommendations for reduced salt intake for blood-pressure control, and the increasing use of noniodized salt by the food industry.”

Processed food producers in the US typically do not use iodized salt. Iodate dough conditioners have been largely replaced by bromate which competes with iodine (as does fluoride). Iodizing salt is the tried and true method for preventing iodine deficiency in the general population, but considering the shortfall lead author Dr. Elizabeth Pearce commented for Medscape:

“That leaves public-health recommendations for groups at risk and the recommendation for women who are pregnant, planning a pregnancy, or breast-feeding is to take an iodine-containing supplement of 150 µg of iodine daily in the form of potassium iodide.”

But the authors note caution must be taken when supplementing iodine:

“Following exposure to high iodine levels, the synthesis of thyroid hormone is normally inhibited via the acute Wolff–Chaikoff effect. If excessive iodine exposure persists, the thyroid is able to “escape” from the acute Wolff–Chaikoff effect within a few days…Conversely, individuals with subtle defects in thyroid hormone synthesis, such as those with Hashimoto’s thyroiditis, may be unable to escape from the acute Wolff–Chaikoff effect, and can develop iodine-induced hypothyroidism. In addition, even small increases in population iodine intake are associated with an increased prevalence of thyroid autoimmunity.”

Bear in mind that by far the most common form of hypothyroid in developed countries is Hashimoto’s thyroiditis (autoimmune thyroiditis). The authors conclude:

“Although substantial progress has been made over the last several decades, iodine deficiency remains a significant public health problem worldwide, including in developed nations. The ongoing monitoring of the population iodine status remains crucially important, and particular attention may need to be paid to monitoring the status of vulnerable populations. There is also a need for ongoing monitoring of iodized salt and other dietary iodine sources in order to prevent excess as well as insufficient iodine nutrition. Finally, it will be essential to coordinate interventions designed to reduce population sodium intake with salt iodization programs in order to maintain adequate levels of iodine nutrition as salt intake declines.”

The LancetA paper just published in the prestigious medical journal The Lancet documented the serious effects of even mild iodine deficiency during pregnancy. The authors state:

“As a component of thyroid hormones, iodine is essential for fetal brain development. Although the UK has long been considered iodine replete, increasing evidence suggests that it might now be mildly iodine deficient. We assessed whether mild iodine deficiency during early pregnancy was associated with an adverse effect on child cognitive development.”

They examined data for measured urinary iodine concentration for 1040 first-trimester pregnant women andlater the intelligence quotient (IQ) in their children at age 8 years and reading ability at 9 years of age. To define iodine deficiency they used the WHO criteria of 150 μg/g in pregnancy. Their data revealed a growing public health problem:

The group was classified as having mild-to-moderate iodine deficiency on the basis of a median urinary iodine concentration of 91·1 μg/L. After adjustment for confounders, children of women with an iodine-to-creatinine ratio of less than 150 μg/g were more likely to have scores in the lowest quartile for verbal IQ, reading accuracy, and reading comprehension than were those of mothers with ratios of 150 μg/g or more. When the less than 150 μg/g group was subdivided, scores worsened ongoing from 150 μg/g or more, to 50—150 μg/g, to less than 50 μg/g.”

For the authors, this is an issue that demands attention:

“Our results show the importance of adequate iodine status during early gestation and emphasise the risk that iodine deficiency can pose to the developing infant, even in a country classified as only mildly iodine deficient. Iodine deficiency in pregnant women in the UK should be treated as an important public health issue that needs attention.”

NIH Office of Dietary SupplementsHow do we go about testing for iodine deficiency when a single spot collection is only accurate for large populations studies and doesn’t reliably apply to the individual and ten spot collections are cumbersome? According to the National Institute of Health Office of Dietary Supplements:

“Iodine status is typically assessed using urinary iodine measurements. Urinary iodine reflects dietary iodine intake directly because people excrete more than 90% of dietary iodine in the urine. Spot urine iodine measurements are a useful indicator of iodine status within populations. However, 24-hour urinary iodine or multiple spot urine measurements are more accurate for individuals.”

Journal of Nutrition 141 (9)Both 10 spot collections and one 24-hour collection are acceptable even though a study published in The Journal of Nutrition found a bit less intra-individual variation (CV) with the 24-hour collection:

“In a prospective, longitudinal, 15-mo study, healthy Swiss women (n = 22) aged 52–77 y collected repeated 24-h urine samples (total n = 341) and corresponding fasting, second-void, morning spot urine samples (n = 177). From the UIC in spot samples, 24-h urinary iodine excretion (UIE) was extrapolated based on the age- and sex-adjusted iodine:creatinine ratio. Measured UIE in 24-h samples, estimated 24-h UIE, and UIC in spot samples were (geometric mean ± SD) 103 ± 28 μg/24 h, 86 ± 33 μg/24 h, and 68 ± 28 μg/L, respectively, with no seasonal differences. Intra-individual variation (mean CV) was comparable for measured UIE (32%) and estimated UIE (33%). The CV tended to be higher for the spot UIC (38%) than for the estimated 24-h UIE (33%).”

American Journal of Clinical NutritionThe issue of how to test for iodine deficiency was examined in a study published in the American Journal of Clinical Nutrition in which the authors showed that the spot check ofurinary iodine concentration (UIC) could be confounded by hydration status, but that a 24-hour collection was not. They investigated how well each tracked the effect of iodine supplementation:

“Urine osmolality (Uosm) and 24-h urinary excretion rates of iodine (24-h UI), sodium, creatinine, and total urine volume (24-h Uvol) were measured in 1046 specimens that were collected at repeated intervals from 1996 to 2003 in a sample of 358 German children aged 6–12 y. Energy intake and food consumption were calculated from 3-d weighed dietary records that were collected in parallel to the urine samples.”

It was only the 24-hour collection which matched the ‘real world’ changes:

“During the 4-y period from 1996 to 1999, the median 24-h UI increased from 87 to 93 μg I/d, whereas urinary iodine concentration (UIC), Uosm, and 24-h Uvol did not change significantly. Thereafter (from 2000 to 2003), UIC stagnated and Uosm decreased, whereas 24-h Uvol and 24-h UI increased. The final median 24-h UI reached 120 μg I/d. Milk, fish, egg, and meat intakes and 24-h sodium excretion were all significant predictors of IS, with an almost doubled contribution from milk intake during the second 4-y period.”

Their conclusion highlights the 24-hour collection as a more dependable metric for iodine sufficiency (IS):

“Our study shows a continuous improvement of IS in a longitudinal sample of German schoolchildren. This improvement was masked when UIC was used as an IS index, especially from 2000 to 2003 because of changes in hydration status. Thus, in research-oriented studies that focus on UIC measurements, hydration status can be a relevant confounder. Longitudinal analyses of 24-h UI in cohort studies may represent an alternative hydration status–independent tool to examine trends in IS and the contribution of relevant foods to IS.”

Clinical EndocrinologyClinical caution: There are a number of studies linking iodine supplementation to increases in autoimmune thyroiditis (Hashimoto’s thyroiditis). This is understandable considering that up-regulating thyroid peroxidase, thyroglobulin and other iodine driven activity could ‘wave a red flag in front of the bull’ in individuals who have lost tolerance and are in the stage of silent autoimmunity. Even iodine introduced cautiously can trigger this problem as described in a paper published in Clinical Endocrinology. The authors state:

“Autoantibodies against the thyroid gland with thyroid peroxidase antibody (TPO-Ab) and thyroglobulin antibody (Tg-Ab) as the most common can often be demonstrated in serum.”

They used these to measure the incidence of thyroid autoimmunity in the Danish population before and after their mandatory iodization of salt:

“Two identical cross-sectional population studies were performed before (Cohort 1 (C1), year 1997–1998, n = 4649, median urinary iodine 61 μg/l) and 4–5 years after (Cohort 2 (C2), year 2004–2005, n = 3570, median urinary iodine 101 μg/l) mandatory iodine fortification of salt was implemented in Denmark. Blood tests were analysed for TPO-Ab and Tg-Ab using sensitive assays.”

There was a definite increase in thyroid autoimmunity:

Antibodies were more frequent in C2 than in C1: TPO-Ab > 30 U/ml, C1 vs C2: 14·3 vs 23·8% (P < 0·001) and Tg-Ab > 20 U/ml, C1 vs C2: 13·7 vs 19·9% (P < 0·001). The C2 vs C1 effect was confirmed in multivariate regression models (C1 reference): TPO-Ab: OR (95% CI): 1·80 (1·59–2·04) and Tg-Ab: 1·49 (1·31–1·69). The increase in the frequency of thyroid antibodies was most pronounced in young women and especially observed at low concentrations of antibodies.”

Clinicians considering iodine supplementation must take care to assess patients for the potential for loss of immune tolerance to thyroid, even when supplementation is undertaken with cautious amounts. The authors conclude:

The prevalence of both TPO-Ab and Tg-Ab was higher 4–5 years after a cautious iodine fortification of salt was introduced in Denmark. The increase was most pronounced in young women and in the low concentrations of antibody. Further studies are needed to evaluate the long-term effects of increased iodine intake on thyroid autoimmunity in the population.”

JAMA Vol 308 No. 23How much iodine should be supplemented during pregnancy and breast feeding? The authors of a paper published in JAMA last December first state:

Dietary iodine requirements are increased during pregnancy due to increased thyroid hormone production, increased renal iodine losses, and fetal iodine requirements. Dietary requirements remain increased in lactation due to the concentration of iodine in breast milk…Adverse effects of iodine deficiency in pregnancy, when the deficiency leads to severe decreases in maternal thyroxine (T4), include include…increased pregnancy loss and infant mortality. Decreases in maternal T4 associated with even mild iodine deficiency may have adverse effects on the cognitive function of offspring, and iodine deficiency remains the leading cause of preventable intellectual disability worldwide.”

This begs the question how much postpartum depression might be contributed to by suboptimal iodine. Regarding supplementation…

“…all US women who are pregnant, lactating, or planning a pregnancy should ingest dietary supplements containing 150 µg of potassium iodide per day. The Endocrine Society has recently advocated that all daily prenatal multivitamins should contain 150 to 200 µg. The addition of 150 µg does not pose a risk, even for women who are iodine replete, because a total iodine intake of as much as 500 too 1100 µg per day is considered safe in pregnancy.”

For selected food sources of iodine and other information see the National Institute of Health Office of Dietary Supplements.

Preeclampsia, an autoimmune disease

Preeclampsia throws into turmoil 5% to 8% of pregnancies worldwide with potentially terrible consequences. Clinicians who participate in the management of pregnancy should appreciate the evidence revealing that preeclampsia is driven by autoimmunity. The authors of a paper recently published in the Journal of Reporductive Immunology note:

“A basic precondition for the development of preeclampsia is the presence of placental trophoblast cells in the maternal blood circulation. On the other hand, while trophoblast cells are present in the blood of all pregnant women, preeclampsia occurs in only 2–5% of them. Evidently, other factors play a crucial role.”

They compared immunological factors including anti-cardiolipin autoantibodies, trophoblast-induced cell-mediated immunity, C3 and C4 complement components, and serum immunoglobulins IgA, IgG, IgM among three groups of women: those with uncomplicated pregnancy, gestational hypertension, or preeclampsia. What did they find?

In the preeclampsia group, there was a significantly higher number of women positive for anti-cardiolipin autoantibodies, trophoblast-induced cell-mediated immunity was elevated, serum IgG was elevated and C4 complement component was reduced.”

In other words the subjects’ immune systems were sharply aroused to attack tissue elements specific to pregnancy. The authors summarize their findings:

“We conclude that both elevated autoimmune reactivity and the higher immune reactivity to trophoblast may contribute to the onset of preeclampsia.”

The authors of a paper published in Biology of Reproduction discuss the autoimmune instigation of hypertension in preeclampsia:

“Pre-eclampsia is a syndrome characterized by inadequate placentation, which is due to deficient trophoblastic invasion of the uterine spiral arteries. This deficiency can lead to placental hypoxia, secretion of proinflammatory cytokines, and release of angiogenic and antiangiogenic factors. Hypoxic conditions in the placenta can promote oxidative stress and the production of angiogenic factors that are antagonized by soluble receptors, which are also elevated in this syndrome. In addition to these factors, the development of hypertension in women with pre-eclampsia may be associated with the renin-angiotensin system and endothelial dysfunction.”

They specifically note the presence of antibodies attacking receptors involved in the regulation of blood pressure:

The presence of antiangiotensin II type 1 receptor autoantibodies is relevant in pre-eclampsia because it has been related to the secretion of antiangiogenic factors through cytokine pathways, indicating that autoimmune mechanisms may participate in the pathophysiology of this syndrome.”

In a fine study published in the journal Hypertension the authors define how a specific B cell subpopulation is a key participant in preeclampsia. They state:

Preeclampsia is a devastating pregnancy-associated disorder affecting 5% to 8% of pregnant women worldwide. It emerges as an autoimmune-driven disease, and, among others, the autoantibodies against angiotensin type 1 receptor II have been proposed to account for preeclampsia symptoms. Despite much attention focused on describing autoantibodies associated with preeclampsia, there is no clue concerning the cell population producing them. CD19+CD5+ B-1a B cells constitute the main source of natural and polyreactive antibodies, which can be directed against own structures.”

They set out to identify the B-cell subpopulation responsible for autoantibody production during preeclampsia. They found that…

“The frequency of CD19+CD5+ cells in peripheral blood of preeclamptic patients is dramatically increased compared with normal pregnant women as analyzed by flow cytometry.”

Interestingly, there was a hormonal component:

“This seems to be driven by the high human chorionic gonadotropin levels present in the serum and placenta supernatant of preeclamptic patients versus normal pregnant women. Not only ≈95% of CD19+CD5+ cells express the human chorionic gonadotropin receptor, but these cells also expand on human chorionic gonadotropin stimulation in a lymphocyte culture.”

Regarding the link with hypertension in preeclampsia compared to normal pregnancies:

“Most importantly, isolated CD19+CD5+ cells produce autoantibodies against angiotensin type 1 receptor II, and CD19+CD5+ cells were further detected in the placenta of preeclamptic but not of normal pregnancies where barely B cells are present.”

The authors conclude:

“In summary, CD19+CD5+ cells emerge as a novel PE marker and their levels correlate with the disease, as well as with the levels of AT1-AA. Their frequency seems to be regulated by increased hCG levels secreted by the placenta during PE and present in the serum. Our data enormously contribute to the understanding of the complex mechanisms leading to the onset of PE. Of importance, our work first identifies the cellular component related to the production of autoantibodies during pregnancy. The detection and quantification of CD19+CD5+ cells in maternal blood may serve as a noninvasive diagnostic tool, which opens vast new therapeutic opportunities.”

Practitioners should not fail to screen for subclinical autoimmunity in patients who wish to become, or already are, pregnant. When autoimmune phenomena are detected the underlying contributing causes can be detected and ameliorated.

SSRI antidepressant use during pregnancy may increase the risk of autism

Summary: The use of selective serotonin reuptake inhibitors (SSRIs, such as Prozac®, Celexa®, Lexapro®, Luvox® and Paxil®) taken during pregnancy—especially the first trimester—appears to increase the risk of autism spectrum disorders. There are evidence-based alternatives to SSRIs that support brain health without putting the fetus at risk.

A study recently published in the journal Archives of General Psychiatry draws attention to a risk of autism spectrum disorders (ASDs) born to mothers who took SSRI antidepressants during their pregnancy. The authors observe:

“The prevalence of autism spectrum disorders (ASDs) has increased over recent years. Use of antidepressant medications during pregnancy also shows a secular increase in recent decades, prompting concerns that prenatal exposure may contribute to increased risk of ASD.”

Therefore they set out to…

“…systematically evaluate whether prenatal exposure to antidepressant medications is associated with increased risk of ASD.”

In order to do so they compared the data for 298 children with ASD to 1507 randomly selected control children, along with the data for both their mothers. Their findings support a cautionary approach to the prenatal use of SSRIs:

“Prenatal exposure to antidepressant medications was reported for 20 case children (6.7%) and 50 control children (3.3%). In adjusted logistic regression models, we found a 2-fold increased risk of ASD associated with treatment with selective serotonin reuptake inhibitors by the mother during the year before delivery (adjusted odds ratio, 2.2), with the strongest effect associated with treatment during the first trimester (adjusted odds ratio, 3.8).”

In other words, the increase in risk for the whole year before delivery was 220%, but limiting the investigation to the first trimester it was 380%. Interestingly…

“No increase in risk was found for mothers with a history of mental health treatment in the absence of prenatal exposure to selective serotonin reuptake inhibitors.”

Meaning that it wasn’t a history of mental health treatment the year before delivery but specifically the use of SSRIs that accounted for the increased risk of ASDs. The authors conclude:

“Although the number of children exposed prenatally to selective serotonin reuptake inhibitors in this population was low, results suggest that exposure, especially during the first trimester, may modestly increase the risk of ASD. The potential risk associated with exposure must be balanced with the risk to the mother or fetus of untreated mental health disorders.”

This would be a troubling dilemma were it not for the fact that therapies supporting brain health are available to treat depression. Serotonin production and signaling, when indicated, can be supported in a physiological and sustainable manner that promotes the brain health of mother and fetus. A categorization and description of key resources that applies to adults as well as children is available in the Parents’ Guide To Brain Health.

The use of any non-aspirin NSAIDs during pregnancy increases the risk of spontaneous abortion

Summary: any type of non-aspirin NSAID must be used only with great caution during pregnancy because they may significantly increase the risk of spontaneous abortion.

Research recently published in the Canadian Medical Association Journal alerts practitioners and pregnant women to the risk for spontaneous abortions caused by the gestational use of any non-aspirin non-steroidal anti-inflammatory drug (NSAID). The authors state:

“We aimed to quantify the association between having a spontaneous abortion and types and dosages of nonaspirin NSAIDs in a cohort of pregnant women.”

They examined data for 4705 women who had a spontaneous abortion compared to ten times as many matched controls, and correlated associations between different types and dosages of non-aspirin NSAIDs with having the spontaneous abortion. Their data raises some serious alarm:

“Adjusting for potential confounders, the use of nonaspirin NSAIDs during pregnancy was significantly associated with the risk of spontaneous abortion (odds ratio [OR] 2.43). Specifically, use of diclofenac (OR 3.09), naproxen (OR 2.64), celecoxib (OR 2.21), ibuprofen (OR 2.19) and rofecoxib (OR 1.83) alone, and combinations thereof (OR 2.64), were all associated with increased risk of spontaneous abortion. No dose–response effect was seen.”

In other words, there as an overall 243% increase in the risk for spontaneous abortion. The increase was over 300% for diclofenac (Voltaren®) and more than 200% for ibuprofen. The authors express the gravity of their concern supported by the data in their conclusion:

Gestational exposure to any type or dosage of nonaspirin NSAIDs may increase the risk of spontaneous abortion. These drugs should be used with caution during pregnancy.”